Objective: To evaluate latanoprost versus bimatoprost given each evening over the 24- hour diurnal curve. Design: Double- masked, 2- center, crossover comparison. Participants: Forty- two of 44 patients with primary o...Objective: To evaluate latanoprost versus bimatoprost given each evening over the 24- hour diurnal curve. Design: Double- masked, 2- center, crossover comparison. Participants: Forty- two of 44 patients with primary open- angle glaucoma (POAG) completed the study. Methods: Consecutive patients were not treated during a baseline 24- hour curve after a glaucoma medicine- free period. They then were randomized to either latanoprost or bimatoprost for a 7- week treatment period. Diurnal curve intraocular pressures (IOPs) were measured at treatment period end at 2 AM, 6 AM, 10 AM, 2 PM, 6 PM, and 10 PM. After the first treatment period, patients were changed to the opposite medicine without a medicine- free period. Diurnal curve measurements were performed again at the end of the second 7- week treatment period. Main Outcome Measure: The 24- hour diurnal IOP. Results: On the last day of treatment, mean 24- hour IOPs were 17.3± 2.8 mmHg for latanoprost and 16.7± 2.4 mmHg for bimatoprost (P=0.01). The 6 PM individual time point for IOP was statistically lower for bimatoprost after a Bonferroni correction (P=0.008). The largest IOP difference at any time point was 0.9 mmHg at 6 PM. The most common side effect was conjunctival hyperemia, which occurred less with latanoprost (n=6) than with bimatoprost (n= 15) (P=0.004). Two patients had their treatments discontinued while on bimatoprost, one due to conjunctival hyperemia and the other due to ocular intolerance. Conclusion: This study indicates that the 24- hour diurnal IOP is statistically lower in POAG with bimatoprost, compared with latanoprost, among patients who tolerated bimatoprost. However, the IOP difference between groups was small and may not be clinically meaningful. In contrast, conjunctival hyperemia seems statistically greater with bimatoprost. The exact clinical importance of conjunctival hyperemia, if any, needs to be clarified further.展开更多
The phenyl-substituted analog of prostaglandin F2α , latanoprost ( Xalatan; Pfizer, Inc, New York, NY) is an intraocular pressure (IOP)-lowering drug for use in patients with glaucoma and ocular hypertension. Latanop...The phenyl-substituted analog of prostaglandin F2α , latanoprost ( Xalatan; Pfizer, Inc, New York, NY) is an intraocular pressure (IOP)-lowering drug for use in patients with glaucoma and ocular hypertension. Latanoprost has been sho wn to stimulate eyelash hypertrichosis and has recently been proposed as a possi ble treatment for alopecia areata involving the eyelashes. We report a case of h ypertrichosis of the eyelashes caused by the prostamide bimatoprost (Lumigan; Al lergan, Inc, Irvine, Calif), a new IOP-lowering drug.展开更多
Purpose: To study the effect of bimatoprost 0.03% (Lumigan) on ocular hemodynamics in patients with open- angle glaucoma or ocular hypertension. Methods: One randomly selected eye of each of 26 patients with open- ang...Purpose: To study the effect of bimatoprost 0.03% (Lumigan) on ocular hemodynamics in patients with open- angle glaucoma or ocular hypertension. Methods: One randomly selected eye of each of 26 patients with open- angle glaucoma or ocular hypertension was enrolled. Each patient received a drop of bimatoprost 0.03% once daily for 1 month. The effect of bimatoprost on ocular circulation was assessed by color Doppler imaging (CDI), which measured peak systolic, end- diastolic blood flow velocities and resistance indices in the ophthalmic, posterior ciliary and central retinal arteries. Retrobulbar hemodynamics by CDI, intraocular pressure by Goldmann applanation tonometer, blood pressure by cuff, and heart rate by palpation were measured at baseline and at 1 month after bimatoprost treatment. Results: Blood flow velocities and r esistance indices in all retrobulbar vessels showed no statistically significant differences between baseline and bimatoprost condition (P > 0.05). Bimatoprost lowered intraocular pressure significantly (P < 0.001), with a mean change of 6.5 mmHg (27% ) after 1 month of treatment. The systolic (P=0.38) and diastolic (P=0.74) blood pressures and pulse rate (P=0.94) did not show statistically significant differences during the study period. Conclusions: The results of this study suggest that topical bimatoprost 0.03% significantly reduces intraocular pressure in patients with open- angle glaucoma or ocular hypertension. However, it does not have any effect on retrobulbar hemodynamics in open- angle glaucoma and ocular hypertension.展开更多
【目的】建立液相色谱-串联质谱(LC-MS/MS)法测定睫毛增长液中比马前列素、他氟乙酰胺、拉坦前列素、曲伏前列素和他氟前列素的分析方法。【方法】样品经50%乙腈的水溶液超声提取,加入4 g NaCl和1 g MgSO;的混合盐沉淀杂质,离心。上层...【目的】建立液相色谱-串联质谱(LC-MS/MS)法测定睫毛增长液中比马前列素、他氟乙酰胺、拉坦前列素、曲伏前列素和他氟前列素的分析方法。【方法】样品经50%乙腈的水溶液超声提取,加入4 g NaCl和1 g MgSO;的混合盐沉淀杂质,离心。上层有机相经微孔滤膜过滤后,用Agilent Poroshell 120 PFP-C18柱(2.7μm,2.1 mm×100 mm)分离,以含5 mmol·L;乙酸铵的0.02%甲酸-乙腈为流动相,梯度洗脱,流速0.5 mL·min;。采用电喷雾正离子源(ESI+),多反应监测(MRM)扫描方式检测,外标法定量。【结果】比马前列素、他氟乙酰胺、拉坦前列素、曲伏前列素和他氟前列素在试验范围内线性良好,r>0.999。考察了膏霜、乳液、凝胶、水4种常见睫毛增长液基质的3个水平的加标回收率。结果回收率均在93.2%~103.5%,相对标准偏差(RSD)均在1.2%~3.4%,检出限(LOD)在0.000 2~1.5μg·g;。在测定的63批睫毛增长液中,检出比马前列素15批。【结论】该方法快速简便,灵敏度高,适用于市售睫毛增长液化妆品中上述5种前列素类似物的测定。展开更多
Purpose:To provide initial validation of the Treatment Satisfaction Survey-Intraocular Pressure(TSS-IOP)quality-of-life survey that analyses specific issues related to side effects,patient satisfaction,and compliance....Purpose:To provide initial validation of the Treatment Satisfaction Survey-Intraocular Pressure(TSS-IOP)quality-of-life survey that analyses specific issues related to side effects,patient satisfaction,and compliance.Methods:A prospective,observational cohort of 250 consecutive patients with primary open-angle glaucoma or ocular hypertension was administered the TSS-IOP survey.Results:Factors that correlated with patient satisfaction included perceived effectiveness of the medicine(F=7.47,P< 0.001),ocular irritation(F=6.06,P< 0.001),conjunctival hyperaemia(F=4.40,P< 0.001),ease of use(F=8.52,P< 0.001),and convenience of use(F=6.90,P < 0.001).Patient compliance,acceptance of their illness,and knowledge of glaucoma were also related to perceived effectiveness of the medicine(P < 0.001),ease of use(P < 0.05)and convenience(P < 0.001).Physician ratings of patient pressure control,side effects,and instillation problems also were significantly correlated to patient satisfaction(R=0.13=0.26,P=0.05-0.001).The physician ratings of patient compliance,however,were not significantly related to any dimension of patient satisfaction(P > 0.05).Among monotherapy prostaglandin treatments,latanoprost demonstrated statistically greater satisfaction than bimatoprost or travoprost regarding conjunctival hyperaemia(P < 0.05)and eye irritation(P < 0.01).Conclusions:This study provides initial evidence that patient satisfaction may be related to compliance,perceived effectiveness of treatment,adverse side effects,ease and convenience of use,acceptance of illness,and knowledge of glaucoma.展开更多
文摘Objective: To evaluate latanoprost versus bimatoprost given each evening over the 24- hour diurnal curve. Design: Double- masked, 2- center, crossover comparison. Participants: Forty- two of 44 patients with primary open- angle glaucoma (POAG) completed the study. Methods: Consecutive patients were not treated during a baseline 24- hour curve after a glaucoma medicine- free period. They then were randomized to either latanoprost or bimatoprost for a 7- week treatment period. Diurnal curve intraocular pressures (IOPs) were measured at treatment period end at 2 AM, 6 AM, 10 AM, 2 PM, 6 PM, and 10 PM. After the first treatment period, patients were changed to the opposite medicine without a medicine- free period. Diurnal curve measurements were performed again at the end of the second 7- week treatment period. Main Outcome Measure: The 24- hour diurnal IOP. Results: On the last day of treatment, mean 24- hour IOPs were 17.3± 2.8 mmHg for latanoprost and 16.7± 2.4 mmHg for bimatoprost (P=0.01). The 6 PM individual time point for IOP was statistically lower for bimatoprost after a Bonferroni correction (P=0.008). The largest IOP difference at any time point was 0.9 mmHg at 6 PM. The most common side effect was conjunctival hyperemia, which occurred less with latanoprost (n=6) than with bimatoprost (n= 15) (P=0.004). Two patients had their treatments discontinued while on bimatoprost, one due to conjunctival hyperemia and the other due to ocular intolerance. Conclusion: This study indicates that the 24- hour diurnal IOP is statistically lower in POAG with bimatoprost, compared with latanoprost, among patients who tolerated bimatoprost. However, the IOP difference between groups was small and may not be clinically meaningful. In contrast, conjunctival hyperemia seems statistically greater with bimatoprost. The exact clinical importance of conjunctival hyperemia, if any, needs to be clarified further.
文摘The phenyl-substituted analog of prostaglandin F2α , latanoprost ( Xalatan; Pfizer, Inc, New York, NY) is an intraocular pressure (IOP)-lowering drug for use in patients with glaucoma and ocular hypertension. Latanoprost has been sho wn to stimulate eyelash hypertrichosis and has recently been proposed as a possi ble treatment for alopecia areata involving the eyelashes. We report a case of h ypertrichosis of the eyelashes caused by the prostamide bimatoprost (Lumigan; Al lergan, Inc, Irvine, Calif), a new IOP-lowering drug.
文摘Purpose: To study the effect of bimatoprost 0.03% (Lumigan) on ocular hemodynamics in patients with open- angle glaucoma or ocular hypertension. Methods: One randomly selected eye of each of 26 patients with open- angle glaucoma or ocular hypertension was enrolled. Each patient received a drop of bimatoprost 0.03% once daily for 1 month. The effect of bimatoprost on ocular circulation was assessed by color Doppler imaging (CDI), which measured peak systolic, end- diastolic blood flow velocities and resistance indices in the ophthalmic, posterior ciliary and central retinal arteries. Retrobulbar hemodynamics by CDI, intraocular pressure by Goldmann applanation tonometer, blood pressure by cuff, and heart rate by palpation were measured at baseline and at 1 month after bimatoprost treatment. Results: Blood flow velocities and r esistance indices in all retrobulbar vessels showed no statistically significant differences between baseline and bimatoprost condition (P > 0.05). Bimatoprost lowered intraocular pressure significantly (P < 0.001), with a mean change of 6.5 mmHg (27% ) after 1 month of treatment. The systolic (P=0.38) and diastolic (P=0.74) blood pressures and pulse rate (P=0.94) did not show statistically significant differences during the study period. Conclusions: The results of this study suggest that topical bimatoprost 0.03% significantly reduces intraocular pressure in patients with open- angle glaucoma or ocular hypertension. However, it does not have any effect on retrobulbar hemodynamics in open- angle glaucoma and ocular hypertension.
文摘Purpose:To provide initial validation of the Treatment Satisfaction Survey-Intraocular Pressure(TSS-IOP)quality-of-life survey that analyses specific issues related to side effects,patient satisfaction,and compliance.Methods:A prospective,observational cohort of 250 consecutive patients with primary open-angle glaucoma or ocular hypertension was administered the TSS-IOP survey.Results:Factors that correlated with patient satisfaction included perceived effectiveness of the medicine(F=7.47,P< 0.001),ocular irritation(F=6.06,P< 0.001),conjunctival hyperaemia(F=4.40,P< 0.001),ease of use(F=8.52,P< 0.001),and convenience of use(F=6.90,P < 0.001).Patient compliance,acceptance of their illness,and knowledge of glaucoma were also related to perceived effectiveness of the medicine(P < 0.001),ease of use(P < 0.05)and convenience(P < 0.001).Physician ratings of patient pressure control,side effects,and instillation problems also were significantly correlated to patient satisfaction(R=0.13=0.26,P=0.05-0.001).The physician ratings of patient compliance,however,were not significantly related to any dimension of patient satisfaction(P > 0.05).Among monotherapy prostaglandin treatments,latanoprost demonstrated statistically greater satisfaction than bimatoprost or travoprost regarding conjunctival hyperaemia(P < 0.05)and eye irritation(P < 0.01).Conclusions:This study provides initial evidence that patient satisfaction may be related to compliance,perceived effectiveness of treatment,adverse side effects,ease and convenience of use,acceptance of illness,and knowledge of glaucoma.
